Multiorgan involvement by amyloid light chain amyloidosis

Guoliang Li*, Dan Han*, Suhua Wei, Huaiyu Wang and Limei Chen

Abstract
Amyloid light chain (AL) amyloidosis is a protein conformational disease. AL amyloidosis results from aggregation of misfolded proteins that are deposited in tissues as amyloid fibrils. Diagnosis of AL amyloidosis can be challenging due to its low incidence and clinical complexity. Therapy requires a risk-adapted approach involving dose reductions and schedule modifications of chemotherapy regimens along with close monitoring of hematologic and organ responses. We herein describe a patient whose condition was diagnosed as systemic AL amyloidosis and presented with splenic rupture as the initial symptom. Congo red staining of the kidney biopsy was positive. The normal structure of the liver and spleen had been replaced by amyloid deposition. The chemotherapy strategy involved a combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone.

Keywords
Amyloid light chain (AL) amyloidosis, Congo red, chemotherapy, splenic rupture, amyloid deposition, multiorgan involvement

Date received: 13 August 2018; accepted: 29 October 2018

Introduction
Amyloid light chain (AL) amyloidosis, namely primary systemic amyloidosis, is a protein conformational disease. AL amyloidosis is caused by unusual small plasma cell clones that produce misfolded light chains, which are then deposited in various tissues.1–3 AL amyloidosis involves

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
*These authors contributed equally to this work.
Corresponding author:
Limei Chen, The First Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an 710061, China. Email: clmml@126.com
multiple organs, including the heart (75%), kidneys (65%), liver (15%), soft tissues (15%), peripheral and/or autonomic nervous system (10%), and gastrointestinal tract (5%). Presenting symptoms of systemic AL amyloidosis are broad and are often a consequence of advanced irreversible organ damage, mimicking other more common diseases of the older population. Thus, it is frequently misdiagnosed. In approximately 40% of cases, AL amyloidosis is diagnosed more than 1 year after the onset of symptoms, and affected patients die within a few months after diagnosis despite modern treatments. Therefore, delayed diagnosis remains a major challenge in initiating effective therapy before organ function deteriorates over time, and recognition of the presenting manifestations is thus imperative for improving survival. Therapy requires a risk-adapted approach. Stem cell transplantation (SCT) is preferred, but only 20% of patients are eligible. Non-transplant candidates are offered chemotherapy. Appropriate treatments target the amyloid deposits and interfere with amyloidogenesis and organ damage. Emerging interventions, such as small RNA interference, are currently being developed. The purpose of the present case report is to provide a better understanding of the clinical features, pathogenesis, diagnosis, therapy, and prognosis of AL amyloidosis and thereby promote the management of amyloidosis.

Figure 1. Hepatic hematoxylin and eosin staining showed a nodular hepatic structure, arterial wall thickening in the portal area, extensive accumulation of homogeneous substance (amyloid) among the hepatic cord cells, and difficult-to-recognize hepatic sinusoids.
Case report

A 45-year-old man was transferred to the emergency department because of sudden left upper quadrant pain. His condition was diagnosed as spontaneous splenic rupture and hemorrhagic shock as confirmed by computed tomography (CT). Emergency splenectomy was performed. Frozen section during surgery and post-operative pathological examination were performed to identify any pathomorphological changes of the liver. Pathological examination revealed a nodular hepatic structure, arterial wall thickening in the portal area, extensive accumulation of a homogeneous substance (amyloid) among the hepatic cord cells, and difficult-to-recognize hepatic sinusoids (Figure 1). The ultrastructure of the spleen was impaired, the red pulp and white pulp were diffusely destroyed, and extensive accumulation of a homogeneous substance (amyloid) was present (Figure 2).

A biopsy specimen from the kidney was stained with Congo red and periodic acid–Schiff; extensive accumulation of a homogeneous substance (amyloid) was present in the glomerulus, indicating renal amyloidosis (Figure 3(a) and (c)). The oxidized Congo red-stained renal tissue specimens (thickness of approximately 6 μm) were fixed in 8% formaldehyde and embedded in paraffin, dewaxed by dimethylbenzene, and hydrated by alcohol and distilled water. The sections were oxidized by KMnO₄ solution (0.5% KMnO₄ and 0.3% H₂SO₄ in a 1:1 ratio) for 5 min to induce degradation of the amyloid deposits according to Wright et al.11 at

![Figure 2](image-url)

**Figure 2.** Splenic hematoxylin and eosin staining showed that the ultrastructure of the spleen was impaired and that the red pulp and white pulp were diffusely destroyed with extensive accumulation of homogeneous substance (amyloid).
25°C; the sections were then bleached by 5% oxalic acid and distilled water two to three times. Finally, they were redyed by alkaline Congo red solution. Amyloid deposition was detected in the glomerulus, and AL amyloidosis was highly suspected (Figure 3(b)). Therefore, the spontaneous splenic rupture was concluded to be a result of the amyloidosis.

CT imaging showed an enlarged liver mass in accordance with diffuse liver damage (Figure 4(a)). The patient and his family had no infectious or chronic diseases. Echocardiography showed a left ventricular ejection fraction of 55%, and the images suggested no obvious changes of either cardiac structure or function. Bone marrow biopsy showed no abnormalities (images not obtained). Repeat hepatic CT imaging still showed a diffusely enlarged liver, as before (Figure 4(b)). Laboratory tests (Table 1) results were normal. Immunophenotyping of the cells raised suspicion for plasma cells, accounting for 0.1% of all nucleated cells. A free light chain (FLC) assay revealed the following: serum \( \kappa \) Ig light chain, 462.5 mg/L; \( \lambda \) Ig light chain, 25.7 mg/L; \( \kappa/\lambda \), 17.9961; and FLC-diff, 436.8 mg/L. Thus, the patient was classified as stage II according to the Mayo cardiac staging system. The combination of these data led to an ultimate diagnosis of AL amyloidosis; however, this took around 1 year.

Because of multiorgan involvement, the patient was treated with the RPCD

![Figure 3. Kidney pathology. (a) Congo red stain showed characteristic amyloid deposition in the glomerulus. (b) Oxidized Congo red stain showed amyloid deposition in the glomerulus, indicating amyloid light chain amyloidosis. (c) Periodic acid–Schiff stain revealed amyloid deposition in the glomerulus.](image-url)
regimen: bortezomib (1.5 mg/m²) 2.8 mg on days 1, 5, 9, and 12; prednisone 100 mg on days 1–4 and 7–10; cyclophosphamide 1.0 mg on days 1, 3, 5, and 7; and thalidomide 50 mg/d. No obvious adverse effects of chemotherapy were observed with the exception of anesthesia of the hands and feet. After four courses of treatment, the FLC assay showed that the serum κ Ig light chain level, λ Ig light chain, κ/λ, and FLC-diff decreased, suggesting a good partial hematologic response (Table 1). Moreover, α-L-fucosidase, alkaline phosphatase, and γ-glutamyl transpeptidase decreased and prealbumin, total protein, and albumin increased (Table 1). Renal evaluation showed that the urine protein decreased and serum creatinine slightly increased. These data in Table 1 indicated an improvement in liver function and stability of renal function.

The latest follow-up was conducted 1 year after treatment initiation. Laboratory tests showed a stable disease state but gradual development of drug tolerance and an insufficient therapeutic response (Table 1).

This study was performed in compliance with the Declaration of Helsinki and was approved by the Ethics Committee of the First Hospital of Xi’an Jiaotong University. Written informed consent was obtained from the patient.

Discussion

The clinical manifestations, laboratory test results, and biopsy findings of this patient supported the diagnosis of AL amyloidosis (highly suspected Ig-κ type) with liver, kidney, and spleen involvement. The process from the beginning to diagnosis lasted around 12 months, further suggesting the challenge in detecting this disease. All ECG recordings during follow-up show no obvious abnormalities, indicating little heart involvement. The patient was classified as stage II according to the Mayo cardiac staging system (troponin T of <0.003 ng/mL, NT-proBNP of 41.01 pg/mL, and FLC-diff of 436.8 mg/L), suggesting a statistical median survival of 40 months. Palladini et al. proposed a staging system predicted by baseline proteinuria and the eGFR for renal involvement and criteria for early assessment of a renal response and progression in patients with AL amyloidosis. In their case, the patient’s renal function was stage I, indicating a low risk of dialysis at 2 years. The cardiac stage and depth of hematologic remission are major predictors of survival for patients with AL amyloidosis. Renal staging in patients with AL amyloidosis has been studied in the context of renal survival; however, hepatic or splenic involvement has not yet been studied.
The lack of a functional spleen in our patient made it difficult to evaluate and compare the influence of splenic involvement in terms of the response to therapy and survival.

Relevant biomarkers are available to detect pre-symptomatic organ damage. NT-proBNP and troponin T have 100% diagnostic sensitivity in cardiac AL amyloidosis. Albuminuria for renal involvement and an abnormal FLC ratio prompt the performance of biomarker-based screening in patients with a high risk of developing AL amyloidosis, aiming to diagnose AL amyloidosis at its early stage and improving the survival rates of patients with AL amyloidosis.10,15–18 Identification of amyloid deposits requires adequate technology and expertise. Patients without definitive findings should be referred to specialized centers.

Some emerging testing approaches have been helpful in the diagnosis of AL amyloidosis. Immunoelectron microscopy can achieve 100% specificity. Diagnostic mass spectrometry can be performed after laser capture microdissection of Congo red-positive areas from slides obtained from paraffin-embedded tissue or on protein extracted from the whole sample, greatly improving diagnostic accuracy. This technique has become the gold standard in many countries.19 Gene sequencing can help to rule out or confirm possible hereditary amyloidosis. Cardiac scintigraphy with bone tracers can differentiate AL from other types of amyloidosis and can spare cardiac biopsies, particularly in patients of advanced age with senile systemic amyloidosis. Bone marrow biopsies and immunofluorescence in situ hybridization of

| Index                   | Initially       | After four courses treatment | One year after treatment |
|-------------------------|----------------|-----------------------------|-------------------------|
| Troponin T              | <0.003 ng/mL   | N/A                         | <0.003 ng/mL            |
| Troponin I              | 2.46 pg/mL     | N/A                         | N/A                     |
| NT-proBNP               | 41.01 pg/mL    | N/A                         | 35.39 pg/mL             |
| α-L-fucosidase          | 44.6 U/L       | 34.6 U/L                    | N/A                     |
| Alkaline phosphatase    | 168 U/L        | 98 U/L                      | 163 U/L                 |
| γ-glutamyl transpeptidase | 211 U/L     | 103 U/L                     | 322 U/L                 |
| Prealbumin              | 112.3 mg/L     | 170.5 mg/L                  | N/A                     |
| Total protein           | 51.9 g/L       | 58.9 g/L                    | N/A                     |
| Albumin                 | 48.9%          | 55.4%                       | N/A                     |
| Scr                     | 41 μmol/L      | 42 μmol/L                   | 45 μmol/L               |
| eGFR                    | 134.99 mL/min/1.73 m² | 134.99 mL/min/1.73 m² | 129.01 mL/min/1.73 m² |
| Urine protein           | 3+             | 2+                          | N/A                     |
| IgA                     | 0.62 g/L       | N/A                         | N/A                     |
| IgM                     | 0.39 g/L       | N/A                         | N/A                     |
| Plasma cells            | 0.1%           | N/A                         | N/A                     |
| κ Ig light chain        | 462.5 mg/L     | 11.5 mg/L                   | 34.80 mg/L              |
| λ Ig light chain        | 25.7 mg/L      | 9.16 mg/L                   | 22.40 mg/L              |
| κ/λ                     | 17.9961        | 1.2555                      | 1.55                    |
| FLC-diff                | 436.8 mg/L     | 2.34 mg/L                   | 12.40 mg/L              |

Table 1. Laboratory values over time.
plasma cells might offer guidance regarding further therapeutic approaches.\textsuperscript{20}

Treatments based on prognostic stratification and risk assessment are important for patients with AL amyloidosis.\textsuperscript{9} Therapeutic regimens include autogenous SCT (ASCT), chemotherapy, targeting of amyloid deposits, and supportive therapy. ASCT is generally preferred, but only 20\% of patients are eligible. Requirements for safe ASCT include an NT-proBNP of <5000 ng/mL, troponin T of <0.06 ng/mL, age of <70 years, involvement of fewer than three organs, and serum creatinine of \( \leq 1.7 \text{mg/dL} \).\textsuperscript{21} Despite normal bone marrow findings, our patient had involvement of three organs and refused to undergo ASCT for economic reasons and personal willingness; therefore, SCT was not recommended. Accordingly, chemotherapy was a better option for his management.

Chemotherapy of AL amyloidosis is based on regimens developed for multiple myeloma and requires a risk-adapted approach, with dose reductions and schedule modifications of the chemotherapeutic regimen and close monitoring of hematologic and organ responses.\textsuperscript{22} Active agents include corticosteroids (dexamethasone, prednisone), alkylating agents (melphalan, cyclophosphamide), immunomodulatory drugs (thalidomide, lenalidomide), and proteasome inhibitors (bortezomib).\textsuperscript{23} Combinations of these drugs have been reported, with patients showing a relatively good response and only mild adverse effects. Hematologic and organ responses were seen in 89\% and 78\% of patients, respectively, but neuropathy was reported in only 44\%,\textsuperscript{24} similar to the present case; therefore, we used this therapeutic strategy in an effort to improve his survival. Moreover, non-chemotherapy approaches targeting amyloid deposits and interfering with amyloidogenesis have increasingly emerged. Doxycycline, polyphenols, anthraquinone 49-iodo-49-deoxydoxorubicin, epigallocatechin gallate, competitive inhibitor of serum amyloid P component, and immunotherapy with a monoclonal anti-light chain antibody (NEOD001) have been reported to improve the clinical status and promote resorption of amyloid deposits in patients with AL amyloidosis.\textsuperscript{20,25–27}

**Limitations**

Our study had several limitations. The bone marrow examination was performed in another hospital and showed no obvious abnormalities during diagnosis; however, no original images were obtained. The results of the immunofluorescence and immunohistochemistry examinations were not obtained. Polarization microscopy and immunoelectron microscopy were unavailable, preventing further confirmation of the amyloid nature. KMnO\textsubscript{4} oxidation alone is not sufficient to differentiate between systemic amyloid A protein (AA) amyloidosis and systemic AL amyloidosis because the resistance or sensitivity of AA deposits and AL deposits may be practically the same, limiting the specificity and sensitivity of this method.\textsuperscript{28}

**Acknowledgments**

We would like to thank the patient and his family members for their cooperation in this study. We would also like to thank Dr. Ping Lan from the Department of Nephrology, First Affiliated Hospital of Xi’an Jiaotong University for contributing to the discussion regarding the kidney biopsy.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
References
1. Zumbo G, Sadeghi-Alavijeh O, Hawkins PN, et al. New and developing therapies for AL amyloidosis. Expert Opin Pharmacother 2017; 18: 139–149.
2. Zhang C, Huang X and Li J. Light chain amyloidosis: where are the light chains from and how they play their pathogenic role? Blood Rev 2017; 31: 261–270.
3. Yamamoto T, Maeda N and Kawasaki H. Hepatic failure in a case of multiple myeloma-associated amyloidosis (kappa-AL). J Gastroenterol 1995; 30: 393–397.
4. Mahmood S, Bridoux F, Venner CP, et al. Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematol 2015; 2: e241–e250.
5. Oran B, Wright DG, Seldin DC, et al. Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 2003; 74: 131–135.
6. Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther 2015; 32: 920–928.
7. Nienhuis HL, Bijzet J and Hazenberg BP. The prevalence and management of systemic amyloidosis in western countries. Kidney Dis (Basel) 2016; 2: 10–19.
8. Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol 2013; 88: 416–425.
9. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989–995.
10. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751–3757.
11. Wright JR, Calkins E and Humphrey RL. Potassium permanganate reaction in amyloidosis. A histologic method to assist in differentiating forms of this disease. Lab Invest 1977; 36: 274–281.
12. Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121: 3420–3427.
13. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541–4549.
14. Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014; 124: 2325–2332.
15. van Gameren II, Lokhorst H, Hazenberg BP, et al. Therapeutic options in systemic AL amyloidosis. Neth J Med 2004; 62: 106–113.
16. Tuzovic M, Yang EH, Baas AS, et al. Cardiac amyloidosis: diagnosis and treatment strategies. Curr Oncol Rep 2017; 19: 46.
17. Thomas PK. Genetic factors in amyloidosis. J Med Genet 1975; 12: 317–326.
18. Tan SY, Pepys MB and Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis 1995; 26: 267–285.
19. Sher T and Gertz MA. Recent advances in the diagnosis and management of cardiac amyloidosis. Future Cardiol 2014; 10: 131–146.
20. Palladini G and Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood 2016; 128: 159–168.
21. Gertz MA, Lacy MQ, Dispenzieri A, et al. Transplantation for amyloidosis. Curr Opin Oncol 2007; 19: 136–141.
22. Nuvolone M and Merlini G. Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis. Expert Opin Ther Targets 2017; 21: 1095–1110.
23. Mhaskar R, Kumar A, Behera M, et al. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Transplant Proc 2009; 41: 893–902.
24. Chari A, Barley K, Jagannath S, et al. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
25. Huang XH and Liu ZH. The clinical presentation and management of systemic light-chain amyloidosis in China. *Kidney Dis (Basel)* 2016; 2: 1–9.

26. Hazenberg BP. Amyloidosis: a clinical overview. *Rheum Dis Clin North Am* 2013; 39: 323–345.

27. Hawkins PN. Hereditary systemic amyloidosis with renal involvement. *J Nephrol* 2003; 16: 443–448.

28. Bely M. Histochemical differential diagnosis and polarization optical analysis of amyloid and amyloidosis. *ScientificWorldJournal* 2006; 6: 154–168.